Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers

Inclusion Criteria: * Aged 18 years or older * Tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic therapy and for which no standard therapy exists * Expansion cohort only: Advanced lymphoma confirmed by histopathology * Measurable or evaluable disease according to RECIST for solid tumors or according to IWRC for NHL tumors * ECOG Performance Status less than or equal to 2 * Life expectancy greater than 12 weeks in the opinion of the Investigator Exclusion Criteria: * Any active or uncontrolled infection * NYHA Grade II or greater congestive heart failure * History of myocardial infarction within 6 months prior to screening * Prior radiation therapy, chemotherapy, hormonal therapy, or immunotherapy within 4 weeks prior to screening or 5 half-lives of the therapy, whichever is shorter